This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2013 May;10(5):248.

doi: 10.1038/nrclinonc.2013.51. Epub 2013 Apr 2.

Haematological cancer: Nilotinib reduces emergence of BCR-ABL mutations in CML

Vanessa Marchesi

PMID: 23546518
DOI: 10.1038/nrclinonc.2013.51

Comment

Haematological cancer: Nilotinib reduces emergence of BCR-ABL mutations in CML

Vanessa Marchesi. Nat Rev Clin Oncol. 2013 May.

. 2013 May;10(5):248.

doi: 10.1038/nrclinonc.2013.51. Epub 2013 Apr 2.

Author

Vanessa Marchesi

PMID: 23546518
DOI: 10.1038/nrclinonc.2013.51

No abstract available

PubMed Disclaimer

Comment on

Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Hochhaus A, Saglio G, Larson RA, Kim DW, Etienne G, Rosti G, De Souza C, Kurokawa M, Kalaycio ME, Hoenekopp A, Fan X, Shou Y, Kantarjian HM, Hughes TP. Hochhaus A, et al. Blood. 2013 May 2;121(18):3703-8. doi: 10.1182/blood-2012-04-423418. Epub 2013 Mar 15. Blood. 2013. PMID: 23502220 Free PMC article. Clinical Trial.

References

1. Blood. 2013 May 2;121(18):3703-8 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Miscellaneous
- NCI CPTAC Assay Portal